Free Trial
NASDAQ:CALC

CalciMedica 8/12/2024 Earnings Report

CalciMedica logo
$1.56 +0.02 (+1.30%)
As of 04/17/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CalciMedica EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CalciMedica's next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

CalciMedica Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
CalciMedica Inc. Common Stock
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

View CalciMedica Profile

More Earnings Resources from MarketBeat